CagriSema vs Tirzepatide 5 Mg: What REIMAGINE 5 Actually Compared

Short Answer: CagriSema Beat Tirzepatide 5 Mg in This Specific Trial

At week 60, once-weekly CagriSema 1.0 mg cagrilintide plus 1.0 mg semaglutide produced 12.4% estimated average weight loss versus 9.1% with once-weekly tirzepatide 5 mg. Both figures use Novo Nordisk’s efficacy estimand. The absolute advantage was 3.3 percentage points.

That is a direct win over tirzepatide 5 mg in adults with type 2 diabetes. It is not a comparison with tirzepatide 10 mg or 15 mg, and it does not establish that CagriSema beats every tirzepatide dose.

HbA1c fell 1.71 percentage points with CagriSema and 1.67 points with tirzepatide, a numerical difference of only 0.04 points. CagriSema met the trial’s noninferiority endpoint for HbA1c, not a claimed superiority endpoint.

For compound-level evidence before comparing offers, read the PeptidePub guides to cagrilintide, semaglutide, and tirzepatide.

REIMAGINE 5 Data Table: Weight, HbA1c, Dose, Population, and Week

REIMAGINE 5 is NCT06534411, a completed, randomized, open-label, parallel-group Phase 3 trial with 1,023 actual participants. It started November 5, 2024, and lists primary completion on June 2, 2026. Participants had type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both. The dual primary endpoints were change in HbA1c and relative body-weight change from baseline to week 60.

These are manufacturer-reported topline results from September 21, 2026. Novo said CagriSema was well tolerated overall and consistent with prior studies, but the release did not include full numerical adverse-event, discontinuation, subgroup, confidence-interval, or missing-data tables. Those details need full peer-reviewed reporting.

Why the Mechanisms Differ: Amylin Plus GLP-1 vs GIP Plus GLP-1

CagriSema combines two molecules and two complementary pathways. Cagrilintide is a long-acting amylin analog associated with satiety and slower gastric emptying. Semaglutide activates the GLP-1 receptor, supporting appetite regulation and glucose control.

Tirzepatide is one molecule that activates GIP and GLP-1 receptors. Counting receptors does not identify a universal winner. REIMAGINE 5 supports the tested products, doses, population, and 60-week endpoints.

Combination results also should not be assigned to cagrilintide alone. In a Phase 2 standalone study, 706 adults without diabetes were randomized across cagrilintide doses. Mean weight reduction at 26 weeks ranged from 6.0% to 10.8% across the 0.3 mg to 4.5 mg groups, compared with 3.0% for placebo.

For standalone evidence, buyer context, and formulation details without confusing them with CagriSema’s fixed combination, see the cagrilintide dosage, reconstitution, and price guide.

What the 5 Mg Comparator Means for Buyers

Dose is the most important qualifier in this result. The Mounjaro prescribing information lists 5 mg, 10 mg, and 15 mg as recommended adult maintenance doses, with 15 mg as the maximum adult dose. REIMAGINE 5 tested only the 5 mg maintenance dose.

The defensible reading is: CagriSema 1.0 mg/1.0 mg beat tirzepatide 5 mg for weight loss at week 60 in adults with type 2 diabetes. “CagriSema beat Zepbound” or “CagriSema is better than tirzepatide” drops the dose and population that make the comparison meaningful.

It is also misleading to place the 12.4% REIMAGINE 5 figure beside results from obesity trials using higher tirzepatide doses and call that head-to-head evidence. Different populations, durations, estimands, rescue rules, and doses can materially change the outcome. Adults with type 2 diabetes also often lose less weight than adults without diabetes in obesity trials.

For broader context on the two established molecules, read semaglutide vs tirzepatide. Keep that comparison separate from this new dose-specific CagriSema result.

Context From REDEFINE 9 and Earlier CagriSema Evidence

REDEFINE 9 tested a different population and comparator. At week 68, Novo reported 21.0% weight loss with CagriSema 1.0 mg/1.0 mg versus 2.0% with placebo in adults with overweight or obesity, using the efficacy estimand. The study also included a 1.7 mg/1.7 mg arm, but the 21.0% headline belongs to the 1.0 mg/1.0 mg arm.

Earlier REDEFINE 1 enrolled 3,417 adults without diabetes. At week 68, the treatment-policy estimate was 20.4% mean weight loss with CagriSema versus 3.0% with placebo. The adherence-focused estimate was 22.7% versus 2.3%.

A 2026 random-effects meta-analysis pooled seven randomized trials with 8,069 participants. CagriSema was associated with 7.58 kg greater weight loss than semaglutide and 9.24 kg greater than cagrilintide.

Together, these findings strengthen the signal for combining amylin and GLP-1 activity. They do not enlarge the REIMAGINE 5 claim. The meta-analysis used pooled cross-trial mean differences, while REDEFINE 9 and REDEFINE 1 used placebo comparators in adults without diabetes. Only REIMAGINE 5 directly compared CagriSema 1.0 mg/1.0 mg with tirzepatide 5 mg in adults with type 2 diabetes.

Current Research-Market Prices: Compare Components and Tirzepatide Separately

PeptidePub catalog data checked September 21, 2026 shows meaningful spreads. Recheck the live pages because prices, codes, stock, shipping, fees, and lots change.

Cagrilintide - Ascension 10 mg: $100 list, $50 after the 50% PEPTIDEPUB code, or $5.00/mg - NextGen 10 mg: $65 list, $58.50 after its 10% peptidepub code, or $5.85/mg - Double R 10 mg: $69.99 list, $59.49 after its 15% PEPTIDEPUB code, or about $5.95/mg

Semaglutide - RetaOne 20 mg: $39 list, $37.05 after its 5% peptidepub code, or about $1.85/mg - RetaOne 10 mg: $29 list, $27.55 after code, or about $2.76/mg - Glacier 15 mg: $53.99 list, $48.59 after its 10% PEPTIDEPUB code, or about $3.24/mg

Tirzepatide - Puratek 60 mg: $89.95, no cataloged code, or about $1.50/mg - NextGen 60 mg: $100 list, $90 after its 10% peptidepub code, or $1.50/mg - LabSourced 60 mg: $149 list, $126.65 after its 15% peptidepub code, or about $2.11/mg

Compare live cagrilintide, semaglutide, and tirzepatide offers separately. Do not combine the cheapest component vials and call them equivalent to Novo’s fixed CagriSema formulation. Once identity, measured fill, and delivered price are known, use the cost-per-dose calculator, then apply current deals.

COA Checks: A CagriSema Blend Must Prove Both Components

A CagriSema blend needs separate confirmation of cagrilintide identity and semaglutide identity, plus quantitative content for each component. One generic purity percentage cannot prove two molecules, their labeled amounts, or their ratio.

Separate vials each need a current lot-matched report. Check the named independent lab, report date, direct verification, exact identity, quantitative net content, purity, sterility, endotoxins, heavy metals, and contaminant screening.

Vendor-level scores are useful screening signals, not proof of a current product lot. Ascension has six of seven PeptidePub fields at vendor level. NextGen, Double R, Puratek, and LabSourced have seven of seven in their reviewed vendor-level sets, but those scores may come from other products.

Among the three tirzepatide price examples, LabSourced has the strongest exact-product evidence: a reviewed Tirzepatide 60 mg report from ILS Laboratories for lot LS-T2602.0.2026, dated September 10, 2026, with all seven PeptidePub fields. Buyers still need to match that lot to the product offered at checkout.

Use vendors and our testing methodology to compare depth, then verify the document with the COA buyer guide. Use the Bodybuilding Health route only when its exact product, current lot evidence, and delivered value win.

FAQ

Did CagriSema beat tirzepatide?

Yes, at the tested doses. CagriSema 1.0 mg/1.0 mg produced 12.4% estimated average weight loss versus 9.1% with tirzepatide 5 mg at week 60 in adults with type 2 diabetes. The result does not cover tirzepatide 10 mg or 15 mg.

Was blood sugar control better with CagriSema?

HbA1c fell 1.71 versus 1.67 percentage points. CagriSema met noninferiority for HbA1c, so the accurate description is similar glycemic lowering within the trial’s margin, not proven superiority.

How many people were in REIMAGINE 5?

ClinicalTrials.gov lists 1,023 actual participants in randomized, open-label, parallel groups.

Is CagriSema the same as buying cagrilintide and semaglutide separately?

No. Novo’s fixed trial product, manufacturing controls, formulation, escalation, and trial oversight do not transfer to separate research vials or retail blends. A blend also needs component-level identity and quantitative testing for both molecules.

What should buyers compare first?

Start with the desired molecule or blend and verify the exact current lot. Require component-level identity and measured content, then compare the delivered price per verified milligram on PeptidePub. Apply a current discount only after the product and lot pass.

Bottom Line: Read the Dose Before You Read the Winner

The useful takeaway is narrow and clear: CagriSema 1.0 mg cagrilintide plus 1.0 mg semaglutide beat tirzepatide 5 mg by 3.3 percentage points of weight loss at week 60 in adults with type 2 diabetes. HbA1c lowering was noninferior, with reductions of 1.71 and 1.67 percentage points.

The comparison does not answer how CagriSema performs against tirzepatide 10 mg or 15 mg. It also does not make separate component vials equivalent to Novo’s fixed formulation. Full peer-reviewed safety, discontinuation, subgroup, confidence-interval, and missing-data tables were not included in the topline release.

Use the evidence pages for cagrilintide, semaglutide, and tirzepatide to choose the compound or combination that fits the research goal. Then compare live offers at the matching cagrilintide, semaglutide, and tirzepatide price pages, inspect current-lot proof through vendors, and apply deals only after the product passes.